** Shares of Guangzhou Innogen Pharmaceutical Group 2591.HK jump 20.1% to HK$31, on track for the biggest one-day pct rise since November 24

** Stock hits its highest level since January 30, on course to snap four consecutive sessions of decline; second-biggest pct gainer in the Hang Seng Composite Index on healthcare .HSCIH, which slips 1%

** China-based pharmaceutical products developer says Investigational New Veterinary Drug application for core product Efsubaglutide Alfa for treatment of companion animal diabetes has been accepted by China's Ministry of Agriculture and Rural Affairs

** Says Phase I clinical trials are expected to commence in the first quarter of 2026

** YTD, stock down 4.8%, benchmark Hang Seng Index .HSI up 3.4%

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))